You are here

Shipments for Pneumococcal Conjugate Vaccine Delayed

MADISON, N.J., Nov. 6 /PRNewswire-FirstCall/ -- Wyeth is informing its customers that the company is experiencing a temporary delay in the shipment of Prevnar -- its pneumococcal conjugate vaccine.

The current delay is attributed to changes in the company's quality assurance processes. The result of these changes will ensure that appropriate documentation is in order to assure that manufactured product conforms to all quality assurance tests. The company believes that shipments will resume shortly, and Wyeth does not expect this to result in a shortage of Prevnar in the marketplace. It is important to note that the vaccine meets all specifications and the changes will not impact the immunogenicity, safety profile, or effectiveness of Prevnar.

Prevnar is the only vaccine available to help prevent pneumococcal meningitis, pneumonia and bacteremia among infants and young children. Since its licensure by the FDA in February 2000, Prevnar has become an important vaccine for children's health -- recommended by ACIP and AAP, and covered by virtually every health insurance plan in the United States.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products and nonprescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

Source: Wyeth

Recent Headlines

Almost 64% of Patients Showed Decreased Hemoglobin A1c Levels
Lifesaving Life Foam for Battlefield, Terrorist Attacks, Trauma
Cell Reprogramming Process May Benefit Patients Prone to Severe Hypoglycemia
Beagles Beat Out Advanced Technology
Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission